SG11202005605SA - Anti-pd-1 antibodies and methods of treatment - Google Patents

Anti-pd-1 antibodies and methods of treatment

Info

Publication number
SG11202005605SA
SG11202005605SA SG11202005605SA SG11202005605SA SG11202005605SA SG 11202005605S A SG11202005605S A SG 11202005605SA SG 11202005605S A SG11202005605S A SG 11202005605SA SG 11202005605S A SG11202005605S A SG 11202005605SA SG 11202005605S A SG11202005605S A SG 11202005605SA
Authority
SG
Singapore
Prior art keywords
antibodies
treatment
methods
Prior art date
Application number
SG11202005605SA
Inventor
Khaled Ali
Neeraj Jagdish Agrawal
Gunasekaran Kannan
Ian Foltz
Zhulun Wang
Daren Bates
Marissa Mock
Shunsuke Takenaka
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG11202005605SA publication Critical patent/SG11202005605SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202005605SA 2018-01-12 2019-01-11 Anti-pd-1 antibodies and methods of treatment SG11202005605SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862616733P 2018-01-12 2018-01-12
US201862770029P 2018-11-20 2018-11-20
PCT/US2019/013205 WO2019140196A1 (en) 2018-01-12 2019-01-11 Anti-pd-1 antibodies and methods of treatment

Publications (1)

Publication Number Publication Date
SG11202005605SA true SG11202005605SA (en) 2020-07-29

Family

ID=65279666

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005605SA SG11202005605SA (en) 2018-01-12 2019-01-11 Anti-pd-1 antibodies and methods of treatment

Country Status (24)

Country Link
US (1) US11518808B2 (en)
EP (1) EP3737694B1 (en)
JP (1) JP2019122373A (en)
KR (1) KR20200110358A (en)
CN (1) CN111727197A (en)
AU (1) AU2019207895A1 (en)
BR (1) BR112020014121A2 (en)
CA (1) CA3087273A1 (en)
CL (1) CL2020001820A1 (en)
CO (1) CO2020009234A2 (en)
CR (2) CR20210319A (en)
ES (1) ES2941740T3 (en)
IL (1) IL275096A (en)
JO (1) JOP20200172A1 (en)
MA (1) MA51631A (en)
MX (1) MX2020007291A (en)
PE (1) PE20211270A1 (en)
PH (1) PH12020550967A1 (en)
SG (1) SG11202005605SA (en)
TN (1) TN2020000142A1 (en)
TW (1) TW201930344A (en)
UY (1) UY38049A (en)
WO (1) WO2019140196A1 (en)
ZA (1) ZA202004735B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10222369B2 (en) 2016-05-17 2019-03-05 Chimera Bioengineering, Inc. Methods for making novel antigen binding domains
EP4342978A3 (en) 2016-09-01 2024-07-03 Chimera Bioengineering Inc. Gold optimized car t-cells
CN106834228B (en) * 2017-01-17 2021-03-23 上海新长安生物科技有限公司 Method for in vitro amplification of CD8+ T cells and cell subsets thereof
JP2021518747A (en) 2018-02-13 2021-08-05 キメラ・バイオエンジニアリング，インコーポレーテッド Regulation of gene expression using RNA destabilizing elements
WO2020023268A1 (en) * 2018-07-24 2020-01-30 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
CA3107192A1 (en) 2018-08-03 2020-02-06 Amgen Research (Munich) Gmbh Antibody constructs for cldn18.2 and cd3
JP2022538829A (en) 2019-06-24 2022-09-06 アムジェン インコーポレイテッド Inhibition of SIRPγ for cancer therapy
US20210046117A1 (en) 2019-08-18 2021-02-18 Chimera Bioengineering, Inc. Combination Therapy with Gold Controlled Transgenes
US20220403023A1 (en) * 2019-10-25 2022-12-22 WuXi Biologics Ireland Limited Novel anti-cd47 antibodies and uses thereof
US20220389119A1 (en) * 2019-11-08 2022-12-08 Amgen Inc. ENGINEERING CHARGE PAIR MUTATIONS FOR PAIRING OF HETERO-IgG MOLECULES
JP2023504884A (en) * 2019-12-05 2023-02-07 ヴィセリックス・インコーポレーティッド Modulators of immune escape mechanisms for universal cell therapy
EP4079763A4 (en) * 2019-12-20 2023-10-11 Guangdong Feipeng Pharmaceutical Co., Ltd Anti-human programmed death -1 (pd-1) monoclonal antibody
US20230075633A1 (en) * 2019-12-20 2023-03-09 Shandong Boan Biotechnology Co., Ltd. Optimized anti-cd3 arm in the generation of t-cell bispecific antibodies for immunotherapy
US12060434B2 (en) * 2020-02-25 2024-08-13 Gensun Biopharma Inc. Trispecific T cell engagers
EP4162257A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
IL299149A (en) 2020-06-26 2023-02-01 Amgen Inc Il-10 muteins and fusion proteins thereof
TW202216778A (en) 2020-07-15 2022-05-01 美商安進公司 Tigit and cd112r blockade
WO2022060878A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for treating prostate cancer
WO2022087458A1 (en) 2020-10-23 2022-04-28 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
CN112516319A (en) * 2020-12-08 2021-03-19 华中农业大学 Combination medicament for treating breast cancer
US11779660B2 (en) * 2021-04-02 2023-10-10 Krystal Biotech, Inc. Viral vectors for cancer therapy
CA3217850A1 (en) 2021-04-27 2022-11-03 Amgen Inc. Modulating product quality of asymmetric multispecific antibodies through the use of temperature
WO2022240722A1 (en) 2021-05-10 2022-11-17 Amgen Inc. Anti-pd-1 antibody dosing for cancer treatment
JP2024522069A (en) * 2021-05-19 2024-06-11 アシャ バイオセラピューティクス，インク． IL-21 Polypeptides and Targeting Constructs
MX2023014415A (en) 2021-06-04 2024-02-08 Amgen Inc T cell engager molecules and uses thereof.
PE20240363A1 (en) 2021-06-04 2024-03-04 Amgen Inc ANTI-CCR8 ANTIBODIES AND USES THEREOF
MX2024001934A (en) 2021-08-12 2024-03-04 Amgen Inc Antibody formulations.
WO2023137161A1 (en) 2022-01-14 2023-07-20 Amgen Inc. Triple blockade of tigit, cd112r, and pd-l1

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
JPS63502716A (en) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー How to enhance glycoprotein stability
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3856559T2 (en) 1987-05-21 2004-04-29 Micromet Ag Multifunctional proteins with predetermined objectives
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
JP3266311B2 (en) 1991-05-02 2002-03-18 生化学工業株式会社 Novel polypeptide and anti-HIV agent using the same
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
AU5702298A (en) 1996-12-03 1998-06-29 Abgenix, Inc. Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
AU2546399A (en) 1998-02-10 1999-08-30 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
DE69909459T2 (en) 1998-04-21 2004-05-27 Micromet Ag CD19XCD3 SPECIFIC POLYPEPTIDES AND THEIR USE
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
JP2003535565A (en) 1998-12-31 2003-12-02 アーチ ディベロプメント コーポレイション Recombinant herpes simplex virus useful for the treatment of neoplastic diseases
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2000054795A1 (en) 1999-03-15 2000-09-21 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6764675B1 (en) 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
ATE312189T1 (en) 2000-01-21 2005-12-15 Biovex Ltd VIRUS STRAINS FOR ONCOLYTIC TREATMENT OF CANCER
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
JP4212897B2 (en) 2001-03-27 2009-01-21 具紀 藤堂 Viruses and their use in therapy
AR036993A1 (en) 2001-04-02 2004-10-20 Wyeth Corp USE OF AGENTS THAT MODULATE THE INTERACTION BETWEEN PD-1 AND ITS LINKS IN THE SUBMODULATION OF IMMUNOLOGICAL ANSWERS
CA2465156C (en) 2001-11-05 2011-10-18 Zymogenetics, Inc. Il-21 antagonists
AU2002357060A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibody categorization based on binding characteristics
PT1576112E (en) 2002-01-18 2012-05-25 Zymogenetics Inc Cytokine receptor zcytor17 multimers
US7736652B2 (en) 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
EP1531850B1 (en) 2002-06-07 2012-02-22 ZymoGenetics, Inc. Use of IL-21 and monoclonal antibody for treating solid cancers
EP1551505B1 (en) 2002-10-04 2010-02-24 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
CN1513993A (en) 2002-12-31 2004-07-21 北京博泰迪生物工程科技开发有限公司 Coding gene sequence of chinese genom cDNA library interleukin 21 and its amino acid sequence of protein
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
JP2007506789A (en) 2003-09-25 2007-03-22 ザイモジェネティクス， インコーポレイテッド Method for treating autoimmune disease using IL-21
KR101229731B1 (en) 2003-10-16 2013-03-07 암젠 리서치 (뮌헨) 게엠베하 Multispecific deimmunized cd3-binders
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
EP1861399B1 (en) 2005-03-14 2011-12-14 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
MX2007012887A (en) 2005-04-18 2007-12-10 Novo Nordisk As Il-21 variants.
NZ563193A (en) * 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
AU2006341398B9 (en) 2005-11-28 2012-02-02 Zymogenetics, Inc. IL-21 receptor antagonists
US20070122413A1 (en) 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
CN101437847A (en) 2006-05-08 2009-05-20 菲洛根有限公司 Antibody-targeted cytokines for therapy
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
AU2007336184A1 (en) 2006-12-21 2008-06-26 Novo Nordisk A/S Interleukin-21 variants with altered binding to the IL-21 receptor
CN101230335B (en) 2007-01-22 2010-08-11 北京奥源和力生物技术有限公司 Herpes simplex virus and recombinant virus as well as host cell, and medicinal combination thereof
CN101230334B (en) 2007-01-22 2011-06-01 北京奥源和力生物技术有限公司 Herpes simplex virus and recombinant virus as well as host cell and medicinal combination thereof
HUE040467T2 (en) 2007-04-03 2019-03-28 Amgen Res Munich Gmbh Cross-species-specific binding domain
ES2432792T5 (en) 2007-04-03 2023-01-16 Amgen Res Munich Gmbh Cross-species specific CD3-epsilon binding domain
WO2008130158A1 (en) 2007-04-19 2008-10-30 Dong-A Pharmaceutical. Co., Ltd A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
DK2217268T3 (en) 2007-12-07 2016-08-15 Zymogenetics Inc MONOCLONAL ANTI-HUMAN IL-21 ANTIBODIES
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
WO2009127691A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US20110159023A1 (en) * 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
ME02485B (en) 2008-10-01 2017-02-20 Amgen Res Munich Gmbh Cross-species-specific psmaxcd3 bispecific single chain antibody
WO2010103038A1 (en) 2009-03-11 2010-09-16 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
RU2598248C2 (en) 2009-04-02 2016-09-20 Роше Гликарт Аг Polyspecific antibodies containing antibody of full length and one-chain fragments fab
MX342623B (en) 2009-06-26 2016-10-06 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format.
KR20120053042A (en) 2009-08-17 2012-05-24 로슈 글리카트 아게 Targeted immunoconjugates
EP2493921B1 (en) 2009-10-30 2018-09-26 Albumedix Ltd Albumin variants
DK2542590T4 (en) 2010-03-05 2020-07-13 Univ Johns Hopkins COMPOSITIONS AND PROCEDURE FOR TARGETED IMMUNOMODULATORY ANTIBODIES AND FUSION PROTEINS
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
US20120258073A1 (en) 2011-02-10 2012-10-11 Christian Gerdes Immunotherapy
CA2829628A1 (en) 2011-03-11 2012-09-20 Amgen Inc. Method of correlated mutational analysis to improve therapeutic antibodies
EA201892619A1 (en) 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
MX353816B (en) 2011-05-05 2018-01-30 Albumedix As Albumin variants.
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
WO2013006795A2 (en) 2011-07-07 2013-01-10 Humanitas International Foundation Antiviral compositions and methods of their use
PT2753355T (en) 2011-09-08 2019-02-01 Univ New York Oncolytic herpes simplex virus and therapeutic uses thereof
KR102096224B1 (en) 2011-10-28 2020-04-03 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 Polypeptide constructs and uses thereof
TWI679212B (en) 2011-11-15 2019-12-11 美商安進股份有限公司 Binding molecules for e3 of bcma and cd3
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
WO2013096732A2 (en) 2011-12-23 2013-06-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of treating or preventing viral diseases by blocking interleukin-21
US9447160B2 (en) 2012-01-19 2016-09-20 University Of Miami Compositions, methods and kits for treatment of cancer and autoimmune diseases
PL2825556T3 (en) 2012-03-16 2018-10-31 Albumedix A/S Albumin variants
PT3489254T (en) 2012-04-30 2022-12-30 Biocon Ltd Targeted/immunomodulatory fusion proteins and methods for making same
WO2013169734A1 (en) 2012-05-07 2013-11-14 Amgen Inc. Anti-erythropoietin antibodies
WO2013169693A1 (en) * 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
ES2848732T3 (en) 2012-08-07 2021-08-11 Roche Glycart Ag Enhanced immunotherapy
GB2512156A (en) 2012-11-08 2014-09-24 Novozymes Biopharma Dk As Albumin variants
WO2014139468A1 (en) 2013-03-15 2014-09-18 Admark Healthcare, Llc Fusion protein molecules and method of use
CN105339389B (en) 2013-05-02 2021-04-27 安奈普泰斯生物有限公司 Antibodies against programmed death-1 (PD-1)
WO2015000585A1 (en) 2013-07-02 2015-01-08 Walter Sebald Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group
CA2917814C (en) 2013-07-11 2022-12-13 The California Institute For Biomedical Research Coiled coil immunoglobulin fusion proteins and compositions thereof
ES2746805T3 (en) 2013-12-12 2020-03-06 Shanghai hengrui pharmaceutical co ltd PD-1 antibody, antigen-binding fragment thereof and medical application thereof
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
MX2016010174A (en) 2014-02-06 2016-11-15 Hoffmann La Roche Interleukine 10 immunoconjugates.
EP3107573B1 (en) 2014-02-19 2018-09-26 Merck Patent GmbH Cancer-targeted il-12 immunotherapy
SG10201913627TA (en) 2014-04-08 2020-03-30 Boston Pharmaceuticals Inc Binding molecules specific for il-21 and uses thereof
CN104403004B (en) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 The preparation and use of antibody interferon heterodimer
EP3233192B1 (en) 2014-12-15 2021-04-14 Washington University Compositions and methods for targeted cytokine delivery
US10662240B2 (en) 2014-12-19 2020-05-26 Mabtech Ab Composition, kit and method for inhibition of IL-21 mediated activation of human cells
WO2016094962A1 (en) 2014-12-19 2016-06-23 Monash University Il-21 antibodies
KR20160113452A (en) 2015-03-20 2016-09-29 (주)엘지하우시스 Core material for vacuum insulation panel and vacuum insulation panel
MX2018001227A (en) 2015-07-30 2018-03-26 Macrogenics Inc Pd-1-binding molecules and methods use thereof.
TWI793062B (en) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Antibody constructs for dll3 and cd3
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
TWI829617B (en) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Antibody constructs for flt3 and cd3
US20180221503A1 (en) 2015-07-31 2018-08-09 Tarveda Therapeutics, Inc. Compositions and methods for immuno-oncology therapies
IL293385A (en) 2015-08-11 2022-07-01 Omniab Inc Novel anti-pd-1 antibodies
US10323091B2 (en) 2015-09-01 2019-06-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
SI3356404T1 (en) 2015-10-02 2021-11-30 F. Hoffmann-La Roche Ag Anti-pd1 antibodies and methods of use
HRP20220436T1 (en) 2015-11-03 2022-05-27 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
FI3394103T3 (en) 2015-12-22 2023-08-30 Regeneron Pharma Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
CN109153977B (en) 2016-01-08 2022-11-01 雷普利穆内有限公司 Oncolytic virus strains
US20210000921A1 (en) 2016-01-11 2021-01-07 Flagship Pioneering Innovations V. Inc. Methods and compositions for modulating thymic function
EA039859B1 (en) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Bispecific antibody constructs binding egfrviii and cd3
US10781264B2 (en) 2016-02-03 2020-09-22 Amgen Research (Munich) Gmbh PSMA and CD3 bispecific T cell engaging antibody constructs
CR20180420A (en) 2016-02-03 2018-12-05 Amgen Inc BIESPECTIFIC ANTIBODY CONSTRUCTS FOR BCMA AND CD3 THAT ARE LINKED TO T-CELLS
AU2017213659B2 (en) 2016-02-05 2024-04-18 Washington University Compositions and methods for targeted cytokine delivery
WO2017134301A1 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Clec9a binding agents
ES2831852T3 (en) 2016-03-17 2021-06-09 Univ Oslo Hf Fusion proteins that target tumor associated macrophages to treat cancer
AU2017238172B2 (en) 2016-03-21 2024-06-27 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
TN2018000337A1 (en) 2016-04-01 2020-01-16 Amgen Inc Chimeric receptors to flt3 and methods of use thereof
WO2017181420A1 (en) 2016-04-22 2017-10-26 Immuno Vir Co., Limited CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY
AU2017290828A1 (en) 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
RU2656181C1 (en) 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Anti-pd-1 antibodies, method for their production, and method of application
US20190169253A1 (en) 2016-08-01 2019-06-06 Virogin Biotech Canada Ltd Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
KR101928981B1 (en) 2016-09-02 2018-12-13 고려대학교 산학협력단 Heterodimeric Fc-fused IL-21 and Pharmaceutical Composition Comprising the Same
CN109952316A (en) 2016-09-14 2019-06-28 北京韩美药品有限公司 A kind of antibody and its function fragment that can specifically combine PD-1
AU2016423559C1 (en) 2016-09-21 2020-11-19 Cstone Pharmaceuticals The novel monoclonal antibodies to programmed death 1 (PD-1)
AU2017331275A1 (en) 2016-09-23 2019-05-16 Oncosec Medical Incorporated Modulating responses to checkpoint inhibitor therapy
ES2898025T3 (en) 2016-11-02 2022-03-03 Jounce Therapeutics Inc Antibodies against PD-1 and their uses
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
CN107082812B (en) 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 It is a kind of restore debilitating immune cell function fusion protein and its application
ES2928718T3 (en) 2017-04-03 2022-11-22 Hoffmann La Roche Immunoconjugates of an anti-PD-1 antibody with a mutant IL-2 or with IL-15
WO2019010222A2 (en) 2017-07-03 2019-01-10 Torque Therapeutics, Inc. Polynucleotides encoding immunostimulatory fusion molecules and uses thereof
WO2019173832A2 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
JP2021519089A (en) 2018-03-28 2021-08-10 オリオニス バイオサイエンシーズ，インコーポレイテッド Bifunctional protein and its preparation
JOP20200259A1 (en) 2018-04-10 2020-10-11 Kite Pharma Inc Chimeric receptors to dll3 and methods of use thereof
JP2021529516A (en) 2018-06-18 2021-11-04 アンウィタ バイオサイエンシス， インク． Cytokine fusion protein and its use
AU2019350466A1 (en) 2018-09-28 2021-04-29 Pierre Fabre Medicament New immunocytokines for the treatment of cancer
KR20210107058A (en) 2018-12-21 2021-08-31 오제 이뮈노테라프틱스 Bifunctional Molecules Against Human PD-1

Also Published As

Publication number Publication date
CL2020001820A1 (en) 2020-10-02
JP2019122373A (en) 2019-07-25
PH12020550967A1 (en) 2021-03-22
ES2941740T3 (en) 2023-05-25
EP3737694B1 (en) 2023-03-01
JOP20200172A1 (en) 2020-07-12
TN2020000142A1 (en) 2022-04-04
KR20200110358A (en) 2020-09-23
US11518808B2 (en) 2022-12-06
ZA202004735B (en) 2023-06-28
BR112020014121A2 (en) 2020-12-01
PE20211270A1 (en) 2021-07-19
EP3737694A1 (en) 2020-11-18
CN111727197A (en) 2020-09-29
CR20200330A (en) 2020-12-23
TW201930344A (en) 2019-08-01
MA51631A (en) 2020-11-18
IL275096A (en) 2020-07-30
AU2019207895A1 (en) 2020-06-18
CA3087273A1 (en) 2019-07-18
CO2020009234A2 (en) 2020-10-30
US20190270817A1 (en) 2019-09-05
UY38049A (en) 2019-07-31
WO2019140196A1 (en) 2019-07-18
MX2020007291A (en) 2020-09-10
CR20210319A (en) 2021-07-27

Similar Documents

Publication Publication Date Title
ZA202004735B (en) Anti-pd-1 antibodies and methods of treatment
IL279053A (en) Anti-pvrig/anti-tigit bispecific antibodies and methods of use
IL276731A (en) Anti-cd73 antibodies and methods of use thereof
IL278772A (en) Anti-ox40 antibodies and methods of use
IL278821A (en) Anti-sirpa antibodies and methods of use thereof
IL267804A (en) Methods of treating cancer with anti-pd-1 antibodies
SG11202010909RA (en) Anti-msr1 antibodies and methods of use thereof
IL269074A (en) Anti-tigit antigen-binding proteins and methods of use thereof
IL270214A (en) Anti-sortilin antibodies and methods of use thereof
IL273196A (en) Claudin6 antibodies and methods of treating cancer
IL277212A (en) Anti-klk5 antibodies and methods of use
IL279648A (en) Anti-sirp-beta1 antibodies and methods of use thereof
EP3645740A4 (en) Anti-pd-1 antibodies and methods of making and using thereof
IL283884A (en) Anti-il-36 antibodies and methods of use thereof
IL280338A (en) Anti-siglec-5 antibodies and methods of use thereof
IL279227A (en) Anti-siglec-7 antibodies and methods of use thereof
SG11202113221RA (en) Anti-cd137l antibodies and methods of using same
IL273538A (en) Anti-trkb monoclonal antibodies and methods of use